The prevalence and treatment rate trends of osteoporosis in postmenopausal women.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
16
05
2023
accepted:
04
08
2023
medline:
28
9
2023
pubmed:
26
9
2023
entrez:
26
9
2023
Statut:
epublish
Résumé
To evaluate the prevalence and treatment of postmenopausal women with osteoporosis in recent years, analyze differences between the prevalence diagnosed by physicians and the prevalence detected by bone mineral density (BMD), and observe the trends of prevalence and treatment rate of osteoporosis in postmenopausal women over time are of great value for the management of osteoporosis. This cross-sectional study collected the data of 4012 postmenopausal women from the National Health and Nutrition Examination Survey (NHANES) from 2005 to 2010, 2013 to 2014 and 2017 to 2018. The prevalence of osteoporosis and osteopenia as well as the treatment rate of osteoporosis were analyzed using Mann-Kendall trend test. Subgroup analysis was conducted in different age, race, body mass index (BMI), diabetes, hypertension, or glucocorticoid use groups. The overall prevalence of physician diagnosed of osteoporosis was 17.4% and was fluctuated in a small range and remained relatively stable within a certain range (Mann-Kendall trend test: Z = 2.20, P = 0.027) during 2005-2018. The prevalence of osteoporosis in postmenopausal women determined by bone mineral density (BMD) examination reached 9.2% during the five cycles. From 2005 to 2018, the prevalence of physician diagnosed osteoporosis fluctuated in a small range. For osteopenia measured by BMD, the prevalence was 59.6% and a gradual increasing trend was found between 2005 and 2018 (Mann-Kendall trend test: Z = 2.20, P = 0.027). Among patients with physician diagnosed osteoporosis, the treatment rate reached 70.49%. The treatment rate of physician diagnosed osteoporosis was decreased from 2005 to 2008, and further decreased from 2009 to 2018 (Mann-Kendall trend test: Z = -2.20, P = 0.027). The actual treatment rate of osteoporosis patients was 55.53%. During 2005-2018, the actual treatment rate of osteoporosis showed a continuous decline (Mann-Kendall trend test: Z = -2.20, P = 0.027). Osteoporosis management might be insufficient and more efforts are needed to improve the diagnosis and treatment rates of osteoporosis in postmenopausal women.
Sections du résumé
BACKGROUND
To evaluate the prevalence and treatment of postmenopausal women with osteoporosis in recent years, analyze differences between the prevalence diagnosed by physicians and the prevalence detected by bone mineral density (BMD), and observe the trends of prevalence and treatment rate of osteoporosis in postmenopausal women over time are of great value for the management of osteoporosis.
METHODS
This cross-sectional study collected the data of 4012 postmenopausal women from the National Health and Nutrition Examination Survey (NHANES) from 2005 to 2010, 2013 to 2014 and 2017 to 2018. The prevalence of osteoporosis and osteopenia as well as the treatment rate of osteoporosis were analyzed using Mann-Kendall trend test. Subgroup analysis was conducted in different age, race, body mass index (BMI), diabetes, hypertension, or glucocorticoid use groups.
RESULTS
The overall prevalence of physician diagnosed of osteoporosis was 17.4% and was fluctuated in a small range and remained relatively stable within a certain range (Mann-Kendall trend test: Z = 2.20, P = 0.027) during 2005-2018. The prevalence of osteoporosis in postmenopausal women determined by bone mineral density (BMD) examination reached 9.2% during the five cycles. From 2005 to 2018, the prevalence of physician diagnosed osteoporosis fluctuated in a small range. For osteopenia measured by BMD, the prevalence was 59.6% and a gradual increasing trend was found between 2005 and 2018 (Mann-Kendall trend test: Z = 2.20, P = 0.027). Among patients with physician diagnosed osteoporosis, the treatment rate reached 70.49%. The treatment rate of physician diagnosed osteoporosis was decreased from 2005 to 2008, and further decreased from 2009 to 2018 (Mann-Kendall trend test: Z = -2.20, P = 0.027). The actual treatment rate of osteoporosis patients was 55.53%. During 2005-2018, the actual treatment rate of osteoporosis showed a continuous decline (Mann-Kendall trend test: Z = -2.20, P = 0.027).
CONCLUSION
Osteoporosis management might be insufficient and more efforts are needed to improve the diagnosis and treatment rates of osteoporosis in postmenopausal women.
Identifiants
pubmed: 37751427
doi: 10.1371/journal.pone.0290289
pii: PONE-D-23-14775
pmc: PMC10522039
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0290289Informations de copyright
Copyright: © 2023 Zhang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Nutr J. 2022 May 17;21(1):33
pubmed: 35578259
JAMA. 2018 Jun 26;319(24):2521-2531
pubmed: 29946735
Osteoporos Int. 2022 Oct;33(10):2137-2153
pubmed: 35687123
Zhonghua Liu Xing Bing Xue Za Zhi. 2022 Apr 10;43(4):509-516
pubmed: 35443305
Arch Osteoporos. 2013;8:138
pubmed: 23575503
Osteoporos Int. 2021 Sep;32(9):1777-1784
pubmed: 33630130
Bone. 2008 Mar;42(3):467-75
pubmed: 18180210
J Bone Miner Res. 1997 Nov;12(11):1761-8
pubmed: 9383679
Arch Osteoporos. 2022 Jan 14;17(1):16
pubmed: 35029750
Reumatol Clin (Engl Ed). 2021 Dec;17(10):570-574
pubmed: 34823823
Ann Intern Med. 2017 Aug 1;167(3):ITC17-ITC32
pubmed: 28761958
Ann Afr Med. 2022 Jan-Mar;21(1):54-57
pubmed: 35313406
Arch Osteoporos. 2022 Feb 4;17(1):31
pubmed: 35122160
Osteoporos Int. 2012 Feb;23(2):771-80
pubmed: 21625885
Int J Environ Res Public Health. 2022 Mar 04;19(5):
pubmed: 35270692
Menopause. 2021 Sep 1;28(9):973-997
pubmed: 34448749
Osteoporos Int. 2022 Oct;33(10):2049-2102
pubmed: 35478046
Int J Occup Med Environ Health. 2022 Jun 8;35(3):273-283
pubmed: 34897291
Subcell Biochem. 2019;91:453-476
pubmed: 30888662
Osteoporos Int. 1997;7 Suppl 3:S84-7
pubmed: 9536309
Int J Mol Sci. 2022 Feb 28;23(5):
pubmed: 35269841
Endocr Pract. 2021 Apr;27(4):379-380
pubmed: 33577971
Clin Med Insights Arthritis Musculoskelet Disord. 2022 Mar 10;15:11795441211072471
pubmed: 35295207
Rev Bras Ginecol Obstet. 2011 Jun;33(6):295-302
pubmed: 21877019
Arch Osteoporos. 2022 Jul 19;17(1):97
pubmed: 35854163
Int J Environ Res Public Health. 2021 Dec 19;18(24):
pubmed: 34948977
Int J Circumpolar Health. 2022 Dec;81(1):2078473
pubmed: 35603589